Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from InMed Pharmaceuticals ( (INM) ) is now available.
On March 27, 2026, InMed Pharmaceuticals disclosed it had received a Nasdaq notification that its common shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive trading days between February 11 and March 26, 2026. The company’s stock will continue trading on the Nasdaq Capital Market under the symbol INM while it has 180 calendar days to restore compliance by achieving a closing bid of at least $1.00 for 10 straight business days.
If InMed does not regain compliance within the initial 180-day grace period, it may qualify for a second 180-day extension provided it meets other Nasdaq listing standards and indicates an intention to cure, potentially via a reverse stock split. Failure to meet the bid-price standard within the allotted periods could ultimately result in delisting and a trading suspension pending any appeal, underscoring a period of heightened listing risk for shareholders and potential pressure on management to pursue corporate actions to support the share price.
The most recent analyst rating on (INM) stock is a Hold with a $0.64 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
The score is primarily held down by weak financial performance (large losses, ongoing cash burn, and data consistency concerns) and a technically bearish trend (below major moving averages with negative MACD). Limited valuation support (no dividend and P/E shown as 0.00) and earnings updates that flag liquidity and regulatory pressures further constrain the rating despite some positive pipeline progress.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical company developing proprietary small-molecule drug candidates that target the CB1 and CB2 receptors. The Vancouver-based company’s pipeline currently comprises three programs focused on disease-modifying treatments for Alzheimer’s disease, as well as ocular and dermatological indications, positioning it in specialized neurology and niche therapeutic markets.
Average Trading Volume: 121,703
Technical Sentiment Signal: Sell
Current Market Cap: $1.91M
See more insights into INM stock on TipRanks’ Stock Analysis page.